Advertisement

Pharmacy World and Science

, Volume 26, Issue 6, pp 333–338 | Cite as

The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999

  • Lamphone Syhakhang
  • Cecilia Stålsby Lundborg
  • Björn Lindgren
  • Göran Tomson
Article

Abstract

Objective: To present a repeated test of the quality of ampicillin, tetracycline, chloroquine and ASA from private pharmacies in Laos in 1997 and 1999, and to discuss the quality in relation to the National Drug Policy Programme.

Method: A total of 115 of 214 licensed private pharmacies were selected in Savannakhet province, a pilot province in the Lao National Drug Policy Programme. The four drugs, if available, were collected at each pharmacy. Thirty tablets of each drug were taken from a selected container. In 1997, 366 samples were analysed and three hundred in 1999. Identity, assay (content of active component) and measurement of weight variation tests were performed. Drug quality was compared mainly according to the standards of the British and United States’ pharmacopoeias.

Results: The percentage of substandard drugs decreased significantly from 46% to 22% between 1997 and 1999 (P < 0.001). Substandard ampicillin and tetracycline were reduced significantly from 67% to 9% and from 38% to 12%, respectively (P < 0.001). In total, 3% vs 1% contained no active ingredient, 12% vs 4% had too little or too much active ingredient, and 35% vs 14% had weight variation outside pharmacopoeial limits.

Conclusion: Drug quality was improved. However, the prevalence of substandard drugs was still unacceptably high, which may result in adverse clinical effect or treatment failure for individual patients.

Community pharmacy Counterfeit drugs Drug quality Lao PDR National Drug Policy Substandard drugs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    World Health Organization. Counterfeit and substandard drugs in Myanmar and Vietnam. Report of a study carried out in cooperation with the governments of Myanmar and Vietnam. Geneva: WHO/EDM/QSM/99.3, 1999.Google Scholar
  2. 2.
    Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 1997; 2: 839–45.CrossRefGoogle Scholar
  3. 3.
    Pecoul B, Chirac P, Trouiller P, Pinel J. Access to essential drugs in poor countries: a lost battle? JAMA 1999; 281: 361–7.CrossRefGoogle Scholar
  4. 4.
    Menkes DB. Hazardous drugs in developing countries. The market may be healthier than the people. BMJ 1997; 315: 1557.Google Scholar
  5. 5.
    Roy J. The menace of substandard drugs. World Health Forum 1994; 15: 406–7.Google Scholar
  6. 6.
    Hanif M, Mobarack MR, Ronan A, Rahman D, Donovan JJJ, Bennish ML. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. BMJ 1995; 311: 88–91.Google Scholar
  7. 7.
    Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001; 357: 1933–6.CrossRefGoogle Scholar
  8. 8.
    Po ALW. Too much, too little, or none at all: dealing with substandard and fake drugs. Lancet 2001; 357: 1904.CrossRefGoogle Scholar
  9. 9.
    Newton P, Proux S, Green M, Smithuis F, Rozendaal J, Prakongpan S, et al. Fake artesunate in southeast Asia. Lancet 2001; 355: 1948–9.CrossRefGoogle Scholar
  10. 10.
    Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999; 5: 18–27.Google Scholar
  11. 11.
    James EF. Martindale: The Extra Pharmacopoeia, 30th edition. London: The Pharmaceutical Press, 1993.Google Scholar
  12. 12.
    World Health Organization. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume I. Geneva: World Health Organization, 1997.Google Scholar
  13. 13.
    Ministry of Health. National health survey, health status of the people in Lao PDR. Vientiane: Ministry of Health, 2001.Google Scholar
  14. 14.
    Paphassarang C, Tomson G, Choprapawon C, Weerasuriya K. The Lao national drug policy: lessons along the journey. Lancet 1995; 345: 433–5.CrossRefGoogle Scholar
  15. 15.
    Stenson B, Tomson G, Syhakhang L. Pharmaceutical regulation in context: the case of Lao People’s Democratic. Health Policy Plan 1997; 12: 329–40.CrossRefGoogle Scholar
  16. 16.
    Syhakhang L. The quality of private pharmacy services in a province of Lao PDR: perceptions, practices and regulatory enforcements [Academic thesis]. Stockholm: Department of Public Health Sciences, Karolinska Institutet, 2002.Google Scholar
  17. 17.
    Syhakhang L, Stenson B, Wahlström R, Tomson G. The quality of public and private pharmacy practices – a cross sectional study in the Savannakhet province, Lao PDR. Eur J Clin Pharmacol 2001; 57: 221–7.CrossRefGoogle Scholar
  18. 18.
    Stenson B, Lindgren BH, Syhakhang L, Tomson G. The quality of drugs in private pharmacies in the Lao People’s Democratic Republic. Int J Risk Safety Med 1998; 11: 243–9.Google Scholar
  19. 19.
    Stenson B, Syhakhang L, Lundborg CS, Eriksson B, Tomson G. Private pharmacy practice and regulation – a randomized trial in Lao PDR. Int J Technol Assess Health Care 2001; 17: 579–89.Google Scholar
  20. 20.
    World Health Organization. Accelerated stability studies of widely used pharmaceutical substances under simulated tropical conditions. Geneva: WHO/Pharm/86.529, 1986.Google Scholar
  21. 21.
    Zak AF, Loseva GI, Ermolova OB, Navolotskaya TI, Yakobson LM. Properties of tetracycline hydrochloride and their changes under various storage conditions. Antibiotiki (Moscow) 1974; 19: 1095–8.Google Scholar
  22. 22.
    Sandell E. Galenisk farmaci [Galenical Pharmacy.] Stockholm: Svensk, Farmaceutisk Tidskrifts Förlag, 1982 [in Swedish].Google Scholar
  23. 23.
    Kenyon TA, Kenyon AS, Sibiya T. Drug quality screening in developing countries: establishment of an appropriate laboratory in Swaziland. Bull World Health Organ 1994; 72: 615–20Google Scholar
  24. 24.
    Stenson B, Syhakhang L, Eriksson B, Tomson G. Real world pharmacy: assessing the quality of private pharmacy practice in the Lao People Democratic Republic. Soc Sci Med 2001; 52: 393–404CrossRefGoogle Scholar
  25. 25.
    Ballereau F, Prazuck T, Schrive I, Lafleuriel MT, Rozec D, Fisch A et al. Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. Am J Trop Med Hyg 1997; 57: 31–6.Google Scholar
  26. 26.
    Nazerali H, Hogerzeil HV. The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study. BMJ 1998; 317: 512–3.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Lamphone Syhakhang
    • 1
  • Cecilia Stålsby Lundborg
    • 2
    • 3
  • Björn Lindgren
    • 4
  • Göran Tomson
    • 5
  1. 1.Food and Drug Department, Ministry of Health, Vientiane, Lao PDR, and Division of International Health (IHCAR)Department of Public Health Sciences, Karolinska InstitutetStockholmSweden
  2. 2.Division of International Health (IHCAR), Department of Public Health SciencesKarolinska InstitutetStockholmSweden
  3. 3.Apoteket AB and Nordic School of Public HealthGothenburgSweden
  4. 4.Medical Products AgencyUppsalaSweden
  5. 5.Health Systems and Policy Research Group, Division of International Health (IHCAR), Department of Public Health SciencesKarolinska Institutet and Doctoral Programme, Medical Management Centre (MMC), Karolinska InstitutetStockholmSweden

Personalised recommendations